Neuromyelitis optica spectrum disorders (NMOSD) is recognized as a distinct clinical entity from multiple sclerosis (MS) based on the disease-specific serum autoantibody aquaporin-4 (AQP4)-IgG. This evidence concerns the gene AQP4 and neuromyelitis optica.